AI Engines For more Details: Perplexity Kagi Labs You
Fungal Skin Infections: Bifonazole is effective against a wide range of fungal infections of the skin, including tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), and tinea versicolor. It works by inhibiting the growth of fungi and reducing the symptoms associated with these infections, such as itching, redness, and scaling.
Fungal Nail Infections: Bifonazole can also be used to treat fungal infections of the nails, known as onychomycosis. It penetrates the nail bed to reach the site of infection and helps eliminate the fungus responsible for the infection. Treatment of fungal nail infections with bifonazole may require several weeks or months to achieve complete resolution.
Mucous Membrane Infections: Bifonazole may be prescribed for fungal infections affecting mucous membranes, such as oral thrush (oral candidiasis) and vaginal yeast infections (vulvovaginal candidiasis). It helps reduce the growth of Candida species, the fungus responsible for these infections, and alleviates associated symptoms like soreness, itching, and discharge.
Topical Application: Bifonazole is typically available as a topical cream, lotion, or solution for external use. It should be applied to the affected area(s) of the skin or nails according to the instructions provided by the healthcare provider or pharmacist. The affected area should be clean and dry before applying the medication.
Duration of Treatment: The duration of treatment with bifonazole depends on the type and severity of the fungal infection being treated. In general, treatment may last for several weeks to months, and it is important to continue using the medication as prescribed even if symptoms improve to prevent recurrence of the infection.
Side Effects: Common side effects associated with bifonazole topical treatment may include mild skin irritation, redness, itching, or burning at the application site. These side effects are usually temporary and resolve on their own. However, if irritation persists or worsens, discontinuation of the medication may be necessary, and a healthcare provider should be consulted.
Contraindications: Bifonazole should not be used in individuals with known hypersensitivity or allergy to the medication or any of its components. It should also be used with caution in pregnant or breastfeeding women, and the potential benefits should be weighed against the risks before use in these populations.
Drug Interactions: Bifonazole used topically is not known to interact significantly with other medications. However, it's essential to inform the healthcare provider about all medications, supplements, and herbal products being used to avoid potential interactions.
Preventive Measures: To reduce the risk of fungal infections, practicing good hygiene, keeping the skin clean and dry, avoiding sharing personal items, and wearing breathable clothing in humid environments can be helpful.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
Acne | 0.2 | -0.2 | |
ADHD | 3.8 | 0.5 | 6.6 |
Age-Related Macular Degeneration and Glaucoma | 1 | 0.5 | 1 |
Allergic Rhinitis (Hay Fever) | 2.5 | 0.8 | 2.13 |
Allergies | 4.9 | 3.2 | 0.53 |
Allergy to milk products | 1.6 | 0.8 | 1 |
Alopecia (Hair Loss) | 2.5 | 2.5 | |
Alzheimer's disease | 3.9 | 9 | -1.31 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.9 | 1.2 | 2.25 |
Ankylosing spondylitis | 4.4 | 2.4 | 0.83 |
Anorexia Nervosa | 0.5 | 3.4 | -5.8 |
Antiphospholipid syndrome (APS) | 2.6 | 0.5 | 4.2 |
Asthma | 0.7 | 1.5 | -1.14 |
Atherosclerosis | 1.2 | 2.2 | -0.83 |
Atrial fibrillation | 4.4 | 2.6 | 0.69 |
Autism | 11.5 | 11.7 | -0.02 |
Barrett esophagus cancer | 0 | 0.4 | 0 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 2 | 1.5 | 0.33 |
Brain Trauma | 0.7 | 0.9 | -0.29 |
Carcinoma | 4 | 3 | 0.33 |
Celiac Disease | 2 | 4 | -1 |
Cerebral Palsy | 1.2 | 1.9 | -0.58 |
Chronic Fatigue Syndrome | 5.3 | 7.9 | -0.49 |
Chronic Kidney Disease | 3 | 3 | 0 |
Chronic Lyme | 0.9 | -0.9 | |
Chronic Obstructive Pulmonary Disease (COPD) | 2 | 1.5 | 0.33 |
Chronic Urticaria (Hives) | 1.3 | 2.4 | -0.85 |
Coagulation / Micro clot triggering bacteria | 1.3 | 1.9 | -0.46 |
Colorectal Cancer | 4.3 | 1.2 | 2.58 |
Constipation | 2 | 1 | 1 |
Coronary artery disease | 2.5 | 1 | 1.5 |
COVID-19 | 11.3 | 17 | -0.5 |
Crohn's Disease | 8.7 | 7.7 | 0.13 |
cystic fibrosis | 0.4 | 1 | -1.5 |
deep vein thrombosis | 0.4 | 1.4 | -2.5 |
Depression | 10.1 | 10.8 | -0.07 |
Dermatomyositis | 0.4 | 0.2 | 1 |
Eczema | 1.1 | 2.8 | -1.55 |
Endometriosis | 3.3 | 1 | 2.3 |
Eosinophilic Esophagitis | 0 | 0 | |
Epilepsy | 3.3 | 3.1 | 0.06 |
Fibromyalgia | 4.5 | 4 | 0.13 |
Functional constipation / chronic idiopathic constipation | 6.2 | 5 | 0.24 |
gallstone disease (gsd) | 2.6 | 0.7 | 2.71 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2 | 1.4 | 0.43 |
Generalized anxiety disorder | 2 | 1.8 | 0.11 |
giant cell arteritis | 0.5 | -0.5 | |
Glioblastoma | 0.4 | -0.4 | |
Gout | 0.5 | -0.5 | |
Graves' disease | 1.5 | 2 | -0.33 |
Halitosis | 0.4 | 0.4 | 0 |
Hashimoto's thyroiditis | 3.2 | 1 | 2.2 |
Hidradenitis Suppurativa | 0.9 | 0.9 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 3.3 | 1.5 | 1.2 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.4 | 0.25 |
hyperglycemia | 0.1 | 2.1 | -20 |
Hyperlipidemia (High Blood Fats) | 0.9 | 0.5 | 0.8 |
hypersomnia | 1 | -1 | |
hypertension (High Blood Pressure | 2.7 | 5.5 | -1.04 |
Hypothyroidism | 1.2 | -1.2 | |
Hypoxia | 1.1 | 1.1 | |
IgA nephropathy (IgAN) | 5.5 | -5.5 | |
Inflammatory Bowel Disease | 5.5 | 11.8 | -1.15 |
Insomnia | 1.3 | 1.4 | -0.08 |
Intelligence | 2 | 1 | 1 |
Intracranial aneurysms | 1.9 | 0.5 | 2.8 |
Irritable Bowel Syndrome | 3.8 | 4.4 | -0.16 |
Liver Cirrhosis | 5.3 | 4.1 | 0.29 |
Long COVID | 9.7 | 11.1 | -0.14 |
Low bone mineral density | 1.5 | -1.5 | |
Lung Cancer | 0.2 | 1.9 | -8.5 |
ME/CFS with IBS | 1.9 | 3.5 | -0.84 |
ME/CFS without IBS | 1.9 | 3 | -0.58 |
Menopause | 0.6 | 0.6 | |
Metabolic Syndrome | 9.1 | 10.2 | -0.12 |
Mood Disorders | 13.5 | 10.8 | 0.25 |
multiple chemical sensitivity [MCS] | 1.3 | 0.5 | 1.6 |
Multiple Sclerosis | 5.6 | 8.6 | -0.54 |
Multiple system atrophy (MSA) | 2.4 | 1.2 | 1 |
Neuropathy (all types) | 1.1 | 0.1 | 10 |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 3.5 | 5.6 | -0.6 |
NonCeliac Gluten Sensitivity | 0.2 | -0.2 | |
Obesity | 10.8 | 5.7 | 0.89 |
obsessive-compulsive disorder | 7.4 | 5.9 | 0.25 |
Osteoarthritis | 3.4 | 0.5 | 5.8 |
Osteoporosis | 1.5 | 1.3 | 0.15 |
pancreatic cancer | 0.4 | 0.4 | |
Parkinson's Disease | 3.4 | 5.5 | -0.62 |
Polycystic ovary syndrome | 3.5 | 2.4 | 0.46 |
Postural orthostatic tachycardia syndrome | 0.5 | 0.7 | -0.4 |
Premenstrual dysphoric disorder | 1.2 | 0.5 | 1.4 |
primary biliary cholangitis | 0.5 | 1.5 | -2 |
Psoriasis | 5.5 | 4.2 | 0.31 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.8 | 4 | 1.2 |
Rosacea | 1.7 | 1 | 0.7 |
Schizophrenia | 7 | 2.7 | 1.59 |
scoliosis | 0.5 | 2 | -3 |
Sjögren syndrome | 2.5 | 3.8 | -0.52 |
Sleep Apnea | 1.7 | 1.9 | -0.12 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.7 | 0.3 | 1.33 |
Stress / posttraumatic stress disorder | 3 | 2.4 | 0.25 |
Systemic Lupus Erythematosus | 4.9 | 2.2 | 1.23 |
Tic Disorder | 1.5 | 2.3 | -0.53 |
Tourette syndrome | 0.2 | 0.4 | -1 |
Type 1 Diabetes | 4.4 | 3.2 | 0.38 |
Type 2 Diabetes | 9.6 | 9.3 | 0.03 |
Ulcerative colitis | 3.2 | 6.6 | -1.06 |
Unhealthy Ageing | 7.2 | 2.4 | 2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.